Protalix BioTherapeutics (NYSE:PLX) Upgraded at StockNews.co

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX – Free Report) from a hold rating to a buy rating in a report published on Thursday. Several other research firms also recently commented on PLX. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Protalix BioTherapeutics in a research note on […]

Related Keywords

Canada , Brazil , Lido , Estado Do Rio , Australia , Russia , United States , Israel , Turkey , California , Dror Bashan , Protalix Biotherapeutics , Virtu Financial , Barclays Plc , Securities Exchange Commission , Lido Advisors , Aptus Capital Advisors , Protalix Biotherapeutics Inc , Free Report , Get Free Report , Exchange Commission , Capital Advisors , California State Teachers Retirement System , Nyse Plx , Mplx , Medical , Upgrade , Stocknews Com ,